ATE313535T1 - Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung - Google Patents
Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellungInfo
- Publication number
- ATE313535T1 ATE313535T1 AT00931877T AT00931877T ATE313535T1 AT E313535 T1 ATE313535 T1 AT E313535T1 AT 00931877 T AT00931877 T AT 00931877T AT 00931877 T AT00931877 T AT 00931877T AT E313535 T1 ATE313535 T1 AT E313535T1
- Authority
- AT
- Austria
- Prior art keywords
- ring
- saturated
- disorders
- substituted
- ring members
- Prior art date
Links
- HCGFLVDMFDHYJD-UHFFFAOYSA-N 2-piperazin-1-ylpyrazine Chemical class C1CNCCN1C1=CN=CC=N1 HCGFLVDMFDHYJD-UHFFFAOYSA-N 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- -1 (i) -O- Chemical class 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical class N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901884A SE9901884D0 (sv) | 1999-05-21 | 1999-05-21 | Novel compounds their use and preparation |
| US13752799P | 1999-06-03 | 1999-06-03 | |
| PCT/SE2000/001017 WO2000076984A2 (en) | 1999-05-21 | 2000-05-19 | Novel compounds, their use and preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE313535T1 true ATE313535T1 (de) | 2006-01-15 |
Family
ID=26663577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00931877T ATE313535T1 (de) | 1999-05-21 | 2000-05-19 | Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1178973B1 (de) |
| KR (1) | KR100722090B1 (de) |
| CN (1) | CN1242995C (de) |
| AT (1) | ATE313535T1 (de) |
| AU (1) | AU777276C (de) |
| BR (1) | BR0010783A (de) |
| CA (1) | CA2374898C (de) |
| DE (1) | DE60024986T2 (de) |
| DK (1) | DK1178973T3 (de) |
| EA (1) | EA005820B1 (de) |
| ES (1) | ES2252004T3 (de) |
| HK (1) | HK1048311B (de) |
| IL (2) | IL146582A0 (de) |
| MX (1) | MXPA01011905A (de) |
| NO (1) | NO322220B1 (de) |
| NZ (1) | NZ515786A (de) |
| WO (1) | WO2000076984A2 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0004244D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| CA2428905A1 (en) | 2000-11-20 | 2002-05-23 | Biovitrum Ab | PIPERAZINYLPYRAZINE COMPOUNDS FOR USE AS ANTAGONISTS OF THE SEROTONIN 5-HT2 RECEPTOR |
| GB0109103D0 (en) * | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| US20030207857A1 (en) | 2001-04-11 | 2003-11-06 | Adam Mavis D. | Phenyl heterocyclyl ethers |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| CA2468015A1 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| DE60330323D1 (de) * | 2002-03-29 | 2010-01-14 | Schering Corp | Stereoselektive alkylierung von chirale 2-methyl-4-geschützte piperazinen |
| WO2003105850A1 (en) * | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
| AU2003243089B2 (en) * | 2002-06-19 | 2010-01-07 | Biovitrum Ab (Publ) | Novel compounds, their use and preparation |
| ES2307102T3 (es) * | 2002-06-19 | 2008-11-16 | Biovitrum Ab (Publ) | Piperazinilpirazinas como moduladores del receptor de la serotonina 5-ht2c. |
| CA2723494C (en) | 2002-06-19 | 2013-04-16 | Biovitrum Ab (Publ) | 2-methyl piperazine derivatives for treatment of serotonin-related disorders |
| US7226925B2 (en) | 2002-06-19 | 2007-06-05 | Biovitrum Ab | Compounds, their use and preparation |
| MXPA05000784A (es) | 2002-07-19 | 2005-06-17 | Biovitrum Ab | Derivados de piperazinil-pirazinona novedosos para el tratamiento de los trastornos relacionados con el receptor 5-ht2a. |
| SE0202287D0 (sv) * | 2002-07-19 | 2002-07-19 | Biovitrum Ab | New compounds |
| AU2004221812B2 (en) | 2003-03-19 | 2010-02-18 | Exelixis Inc. | Tie-2 modulators and methods of use |
| CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| EP1670460B1 (de) | 2003-10-10 | 2014-11-26 | Bristol-Myers Squibb Company | Pyrazol-derivate als cannabinoid-rezeptor-modulatoren |
| CN1972914A (zh) | 2004-03-31 | 2007-05-30 | 詹森药业有限公司 | 作为组胺h3受体配合体的非咪唑杂环化合物 |
| EP1792629A4 (de) | 2004-08-25 | 2010-08-25 | Takeda Pharmaceutical | Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür |
| GT200500317A (es) | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
| ATE460415T1 (de) | 2004-11-29 | 2010-03-15 | Warner Lambert Co | Therapeutische pyrazoloä3,4-büpyridine und - indazole |
| MX2007012082A (es) | 2005-03-31 | 2007-11-20 | Pfizer Prod Inc | Derivados de ciclopentapiridina y tetrahidroquinolina. |
| AR054849A1 (es) | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
| CA2645099A1 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Methods for modulating bladder function |
| PA8720901A1 (es) * | 2006-03-24 | 2008-11-19 | Wyeth Corp | Tratamiento del dolor |
| EP2727585A1 (de) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo Screening-Methode |
| KR101372941B1 (ko) | 2006-05-30 | 2014-03-14 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ３ 수용체 조절제로서의 치환된 피리딜 아미드 화합물 |
| UA101166C2 (ru) | 2007-09-21 | 2013-03-11 | Аррей Биофарма Инк. | Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета |
| EP2216023A4 (de) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | Kondensiertes pyridinderivat und seine verwendung |
| BRPI0820481A2 (pt) | 2007-11-20 | 2015-06-16 | Janssen Pharmaceutica Nv | Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina |
| AU2010313392B2 (en) | 2009-10-30 | 2015-07-09 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
| CA2779107C (en) | 2009-10-30 | 2017-05-30 | Steven J. Coats | Pyrimidine compounds as delta opioid receptor modulators |
| JP5770198B2 (ja) * | 2009-10-30 | 2015-08-26 | ヤンセン ファーマシューティカ エヌ．ベー． | オピオイド受容体調節因子としてのフェノキシ置換ピリミジン |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| CA2812935A1 (en) | 2010-09-28 | 2012-04-05 | Bristol-Myers Squibb Company | Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals |
| CN104168958B (zh) | 2011-12-22 | 2017-12-01 | 坎塞拉有限公司 | 可用于治疗炎症和癌症的二芳基磺酰胺 |
| GB201312131D0 (en) * | 2013-07-05 | 2013-08-21 | Proximagen Ltd | Drug combination and its use in therapy |
| GB201312129D0 (en) * | 2013-07-05 | 2013-08-21 | Proximagen Ltd | Drug combination and its use in therapy |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN105348204B (zh) * | 2015-11-18 | 2018-09-14 | 乳源瑶族自治县大众药品贸易有限公司 | 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途 |
| CN105461635B (zh) * | 2015-11-18 | 2018-06-08 | 乳源瑶族自治县大众药品贸易有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
| CN108409729B (zh) * | 2017-02-09 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途 |
| JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| CN109111383B (zh) * | 2018-09-14 | 2020-11-24 | 广东东阳光药业有限公司 | 2-取代的二苯硫醚衍生物及其用途 |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| CN114394887A (zh) * | 2022-01-28 | 2022-04-26 | 江苏锐鸣材料科技有限公司 | 一种苯基氧乙醇化合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI193974A7 (de) * | 1973-07-13 | 1975-01-14 | Merck & Co Inc | |
| GB9313913D0 (en) * | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
| GB9420999D0 (en) * | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| WO1999058490A2 (en) * | 1998-05-08 | 1999-11-18 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
-
2000
- 2000-05-19 CN CNB008102449A patent/CN1242995C/zh not_active Expired - Fee Related
- 2000-05-19 EP EP00931877A patent/EP1178973B1/de not_active Expired - Lifetime
- 2000-05-19 IL IL14658200A patent/IL146582A0/xx unknown
- 2000-05-19 ES ES00931877T patent/ES2252004T3/es not_active Expired - Lifetime
- 2000-05-19 DK DK00931877T patent/DK1178973T3/da active
- 2000-05-19 KR KR1020017014888A patent/KR100722090B1/ko not_active Expired - Fee Related
- 2000-05-19 DE DE60024986T patent/DE60024986T2/de not_active Expired - Lifetime
- 2000-05-19 NZ NZ515786A patent/NZ515786A/en not_active IP Right Cessation
- 2000-05-19 CA CA002374898A patent/CA2374898C/en not_active Expired - Fee Related
- 2000-05-19 AT AT00931877T patent/ATE313535T1/de active
- 2000-05-19 BR BR0010783-2A patent/BR0010783A/pt not_active Application Discontinuation
- 2000-05-19 AU AU49690/00A patent/AU777276C/en not_active Ceased
- 2000-05-19 EA EA200101223A patent/EA005820B1/ru not_active IP Right Cessation
- 2000-05-19 HK HK03100371.6A patent/HK1048311B/zh not_active IP Right Cessation
- 2000-05-19 WO PCT/SE2000/001017 patent/WO2000076984A2/en not_active Ceased
- 2000-05-19 MX MXPA01011905A patent/MXPA01011905A/es active IP Right Grant
-
2001
- 2001-11-19 IL IL146582A patent/IL146582A/en not_active IP Right Cessation
- 2001-11-21 NO NO20015686A patent/NO322220B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000076984A2 (en) | 2000-12-21 |
| CA2374898C (en) | 2009-12-08 |
| AU4969000A (en) | 2001-01-02 |
| MXPA01011905A (es) | 2004-03-19 |
| DK1178973T3 (da) | 2006-05-08 |
| EA005820B1 (ru) | 2005-06-30 |
| KR100722090B1 (ko) | 2007-05-25 |
| CN1360583A (zh) | 2002-07-24 |
| KR20020016795A (ko) | 2002-03-06 |
| NO20015686L (no) | 2002-01-15 |
| AU777276C (en) | 2005-07-07 |
| NZ515786A (en) | 2004-01-30 |
| CN1242995C (zh) | 2006-02-22 |
| EP1178973B1 (de) | 2005-12-21 |
| WO2000076984A8 (en) | 2001-07-19 |
| EP1178973A2 (de) | 2002-02-13 |
| ES2252004T3 (es) | 2006-05-16 |
| AU777276B2 (en) | 2004-10-07 |
| WO2000076984A3 (en) | 2001-02-08 |
| IL146582A0 (en) | 2002-07-25 |
| IL146582A (en) | 2010-04-29 |
| CA2374898A1 (en) | 2000-12-21 |
| HK1048311B (zh) | 2006-08-11 |
| NO322220B1 (no) | 2006-08-28 |
| NO20015686D0 (no) | 2001-11-21 |
| EA200101223A1 (ru) | 2002-06-27 |
| DE60024986D1 (de) | 2006-01-26 |
| DE60024986T2 (de) | 2006-07-27 |
| BR0010783A (pt) | 2002-04-09 |
| HK1048311A1 (en) | 2003-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60024986D1 (de) | Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung | |
| IS6459A (is) | Arýl sambrædd azapólýsýklísk efnasambönd | |
| GEP20104959B (en) | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | |
| UA66825C2 (uk) | Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| MY136270A (en) | Processes and intermediates for preparing anti-cancer compounds | |
| WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
| BG107120A (bg) | Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства | |
| SG128491A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| SE0104332D0 (sv) | Therapeutic agents | |
| ATE227293T1 (de) | 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one | |
| BG104998A (en) | Isothiazole derivatives useful as anticancer agents | |
| ATE211474T1 (de) | Galanthamin derivate, verfahren zu ihrer herstellung und ihre verwendung als medikamente | |
| MY133474A (en) | Aryl fused azapolycyclic compounds | |
| ATE66913T1 (de) | Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen. | |
| ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
| DE69618050D1 (de) | Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung | |
| SE9901884D0 (sv) | Novel compounds their use and preparation | |
| ES2111086T3 (es) | Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos. | |
| WO2002094768A3 (en) | Aza hydroxylated ethyl amine compounds | |
| WO2005007630A3 (en) | Aryl fused azapolycyclic compounds | |
| ATE359995T1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit | |
| WO2002040465A3 (en) | Aryloxy piperidinyl indoles for treating depression | |
| MXPA04003688A (es) | Compuestos azapoliciclicos condensados con arilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1178973 Country of ref document: EP |